Pharmaceutical Patent Cliff Tracker

Every marketed drug with a patent expiring, organised by year 2015 → 2030. Each year shows sponsor, therapeutic area, drug class, and patent type. Free + sourced from FDA Orange Book + USPTO Patent Public Search.

Every marketed drug in our index with at least one patent expiring, organised by year. Pick a year to see the full list joined to sponsor, drug class, therapeutic area, and patent type. Forward-looking years are forecasts; the past is a historical archive.

Browse by year

Biggest single-year cliffs (historical + forecast)

• 2026 patent cliff — live tracking, current year
• 2027 patent cliff — forward-looking forecast
• 2023 patent cliff — Humira, Stelara start cliff
• 2025 patent cliff — Ozempic class, Eliquis dynamics

Related tools + data

• Patent cliff revenue calculator — model originator revenue erosion
• Biosimilar tracker — who's competing for each post-cliff originator
• Patent expiries dataset (CSV / JSON)
• API access for programmatic patent lookups

Why patent cliffs matter

• Originators: revenue erosion typically 30–80% within 24 months; defended via formulation patents, indication expansion, next-gen molecules
• Generic / biosimilar sponsors: entry timing depends on paragraph IV outcomes, settlements, FDA exclusivity
• Payers: 15–35% list-price discounts (biosimilar); higher for small-molecule generics
• Investors: single biggest revenue-modelling input for big pharma